Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 17, Issue 1, 2011, Pages 61-64

  Leverenz, James B ^a,b,c   Stennis Watson, G ^a,c   Shofer, Jane ^a   Zabetian, Cyrus P ^a,b   Zhang, Jing ^b   Montine, Thomas J ^b  

^a Education   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Cognition; Dementia; Parkinson disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; TAU PROTEIN;

ADULT; AGED; ARTICLE; CATEGORY FLUENCY; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; COGNITION; DEMENTIA; DIGIT SYMBOL; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LOGICAL MEMORY; LUMBAR PUNCTURE; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM; TRAILS B MINUS;

ADULT; AGE OF ONSET; AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; TAU PROTEINS;

EID: 78651080087     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.10.003     Document Type: Article

References (17)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of Neurology 2003, 60:387-392.
2. Buter T.C., van den Hout A., Matthews F.E., Larsen J.P., Brayne C., Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008, 70:1017-1022.
3. Sonnen J.A., Postupna N., Larson E.B., Crane P.K., Rose S.E., Montine K.S., et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 2010, 20:654-659.
4. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002, 59:102-112.
5. Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006, 67:1605-1611.
6. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
7. Sonnen J.A., Montine K.S., Quinn J.F., Kaye J.A., Breitner J.C., Montine T.J. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008, 7:704-714.
8. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343-349.
9. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007, 69:631-639.
10. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
11. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010. doi:10.1002/mds.23287.
12. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008, 129:526-529.
13. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:745-752.
14. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
15. Lezak M.D. Neuropsychological assessment 2004, Oxford University Press, New York. 4th ed. D.B. Howieson, D.W. Loring, M.D. Lezak (Eds.).
16. Aarsland D., Bronnick K., Larsen J.P., Tysnes O.B., Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72:1121-1126.
17. Goldman W.P., Baty J.D., Buckles V.D., Sahrmann S., Morris J.C. Cognitive and motor functioning in Parkinson disease: subjects with and without questionable dementia. Arch Neurol 1998, 55:674-680.